Generali Investments CEE investicni spolecnost a.s. Invests $137,000 in BioNTech SE (NASDAQ:BNTX)

Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech SE (NASDAQ:BNTX) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 1,200 shares of the company’s stock, valued at approximately $137,000.

Other institutional investors also recently modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich bought a new stake in BioNTech during the fourth quarter worth $7,128,000. Raymond James Financial Inc. bought a new stake in BioNTech during the fourth quarter worth $584,000. Charles Schwab Investment Management Inc. grew its holdings in BioNTech by 39.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company’s stock worth $21,349,000 after buying an additional 53,319 shares in the last quarter. Quintet Private Bank Europe S.A. grew its holdings in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock worth $88,000 after buying an additional 700 shares in the last quarter. Finally, SBI Securities Co. Ltd. bought a new stake in BioNTech during the fourth quarter worth $391,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently issued reports on BNTX. HC Wainwright reiterated a “buy” rating and set a $150.00 price target on shares of BioNTech in a report on Monday, November 18th. Truist Financial assumed coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective for the company. Wells Fargo & Company assumed coverage on BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price objective for the company. Canaccord Genuity Group upped their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, BioNTech currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.72.

BioNTech Stock Down 1.8 %

BNTX stock opened at $108.78 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The company has a market capitalization of $26.08 billion, a price-to-earnings ratio of -51.80 and a beta of 0.30. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The stock has a fifty day moving average of $116.91 and a 200-day moving average of $112.93.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.